Literature DB >> 33029615

Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk.

Noé Corpataux1, Alessandro Spirito1, Felice Gragnano1, Lukas Vaisnora1, Roberto Galea1, Stefano Svab1, Giuseppe Gargiulo2, Thomas Zanchin1, Christian Zanchin1, George C M Siontis1, Fabien Praz1, Jonas Lanz1, Lukas Hunziker1, Stefan Stortecky1, Thomas Pilgrim1, Lorenz Räber1, Davide Capodanno3,4, Philip Urban5, Stuart Pocock6, Dik Heg7, Stephan Windecker1, Marco Valgimigli1,8.   

Abstract

AIMS: To validate the set of clinical and biochemical criteria proposed by consensus by the Academic Research Consortium (ARC) for High Bleeding Risk (HBR) for the identification of HBR patients. These criteria were categorized into major and minor, if expected to carry in isolation, respectively, ≥4% and <4% Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding risk within 1-year after percutaneous coronary intervention (PCI). High bleeding risk patients are those meeting at least 1 major or 2 minor criteria. METHODS AND
RESULTS: All patients undergoing PCI at Bern University Hospital, between February 2009 and September 2018 were prospectively entered into the Bern PCI Registry (NCT02241291). Age, haemoglobin, platelet count, creatinine, and use of oral anticoagulation were prospectively collected, while the remaining HBR criteria except for planned surgery were retrospectively adjudicated. A total of 16 580 participants with complete ARC-HBR criteria were included. After assigning 1 point to each major and 0.5 point to each minor criterion, we observed for every 0.5 score increase a step-wise augmentation of BARC 3 or 5 bleeding rates at 1 year ranging from 1.90% among patients fulfilling no criterion, through 4.01%, 5.98%, 7.42%, 8.60%, 12.21%, 12.29%, and 17.64%. All major and five out of six minor criteria, conferred in isolation a risk for BARC 3 or 5 bleeding at 1 year exceeding 4% at the upper limit of the 95% confidence intervals.
CONCLUSION: All major and the majority of minor ARC-HBR criteria identify in isolation patients at HBR. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Academic Research Consortium; Bleeding; Percutaneous coronary intervention; Validation

Mesh:

Substances:

Year:  2020        PMID: 33029615     DOI: 10.1093/eurheartj/ehaa671

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  21 in total

Review 1.  Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk.

Authors:  Yunosuke Matsuura; Kohei Moribayashi; Koichi Kaikita
Journal:  J Atheroscler Thromb       Date:  2022-08-06       Impact factor: 4.394

Review 2.  Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention.

Authors:  Francesco Pelliccia; Felice Gragnano; Vincenzo Pasceri; Arturo Cesaro; Marco Zimarino; Paolo Calabrò
Journal:  J Clin Med       Date:  2022-06-21       Impact factor: 4.964

3.  Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy.

Authors:  Ming-Yun Ho; Po-Wei Chen; Wen-Han Feng; Chun-Hung Su; Sheng-Wei Huang; Chung-Wei Cheng; Hung-I Yeh; Ching-Pei Chen; Wei-Chun Huang; Ching-Chang Fang; Hui-Wen Lin; Sheng-Hsiang Lin; I-Chang Hsieh; Yi-Heng Li
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

Review 4.  Bleeding avoidance strategies in percutaneous coronary intervention.

Authors:  Davide Capodanno; Deepak L Bhatt; C Michael Gibson; Stefan James; Takeshi Kimura; Roxana Mehran; Sunil V Rao; Philippe Gabriel Steg; Philip Urban; Marco Valgimigli; Stephan Windecker; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2021-08-23       Impact factor: 32.419

5.  Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial.

Authors:  Felice Gragnano; Marcel Zwahlen; Pascal Vranckx; Dik Heg; Kurt Schmidlin; Christian Hamm; Philippe Gabriel Steg; Giuseppe Gargiulo; Eugene P McFadden; Yoshinobu Onuma; Ply Chichareon; Edouard Benit; Helge Möllmann; Luc Janssens; Sergio Leonardi; Aleksander Zurakowski; Alessio Arrivi; Robert Jan Van Geuns; Kurt Huber; Ton Slagboom; Paolo Calabrò; Patrick W Serruys; Peter Jüni; Marco Valgimigli; Stephan Windecker
Journal:  J Am Heart Assoc       Date:  2022-03-01       Impact factor: 6.106

6.  Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients.

Authors:  Jung-Joon Cha; Jae Hyoung Park; Hyung Joon Joo; Soon Jun Hong; Tae Hoon Ahn; Byeong-Keuk Kim; WonYong Shin; Sung Gyun Ahn; JungHan Yoon; Yong Hoon Kim; Yun-Hyeong Cho; Woong Chol Kang; Weon Kim; Young-Hyo Lim; Hyeon Cheol Gwon; Woong Gil Choi; Do-Sun Lim
Journal:  Aging (Albany NY)       Date:  2021-03-12       Impact factor: 5.955

7.  Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland.

Authors:  Jasper Boeddinghaus; Thomas Nestelberger; Christoph Kaiser; Raphael Twerenbold; Gregor Fahrni; Roland Bingisser; Nina Khanna; Sarah Tschudin-Sutter; Andreas Widmer; Raban Jeger; Beat Kaufmann; Otmar Pfister; Christian Sticherling; Christian Müller; Stefan Osswald; Michael J Zellweger; Michael Kühne
Journal:  Int J Cardiol Heart Vasc       Date:  2020-12-04

8.  Clinical values of resting electrocardiography in patients with known or suspected chronic coronary artery disease: a stress perfusion cardiac MRI study.

Authors:  Yodying Kaolawanich; Rawiwan Thongsongsang; Thammarak Songsangjinda; Thananya Boonyasirinant
Journal:  BMC Cardiovasc Disord       Date:  2021-12-28       Impact factor: 2.298

9.  Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI.

Authors:  Hao-Yu Wang; Bo Xu; Chen-Xi Song; Chang-Dong Guan; Li-Hua Xie; Yan-Yan Zhao; Zhong-Xing Cai; Sheng Yuan; Ke-Fei Dou
Journal:  J Interv Cardiol       Date:  2022-01-13       Impact factor: 2.279

10.  A Prospective, observational, Italian multi-center registry of self-aPposing® cOronary Stents in patients presenting with ST-segment Elevation Myocardial InfarcTION: The iPOSITION registry.

Authors:  Livio Giuliani; Federico Archilletti; Giuseppe Andò; Serena Rossi; Giorgio Sacchetta; Giuseppe De Iaco; Francesco Saporito; Marco Contarini; Rosario Parisi; Sabina Gallina; Marco Zimarino; Juan Luis Gutiérrez-Chico; Nicola Maddestra
Journal:  Cardiol J       Date:  2021-05-04       Impact factor: 2.737

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.